Related Experiment Videos

Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator

Fuad N Ziyadeh1

  • 1Penn Center for Molecular Studies of Kidney Diseases, Renal-Electrolyte and Hypertension Division, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. ziyadeh@mail.med.upenn.edu

Journal of the American Society of Nephrology : JASN
|December 20, 2003
PubMed

Insights

High blood sugar (hyperglycemia) drives diabetic kidney disease. Targeting transforming growth factor-beta (TGF-beta) with antibodies prevents and reverses kidney damage in diabetic mice.

Area of Science:

  • Nephrology
  • Endocrinology
  • Molecular Biology

Background:

  • Hyperglycemia is a key factor in diabetic nephropathy development.
  • Transforming growth factor-beta (TGF-beta) is implicated as a mediator of high glucose effects on the kidney.

Purpose of the Study:

  • To investigate the role of TGF-beta signaling in diabetic kidney disease.
  • To evaluate the therapeutic potential of blocking TGF-beta in diabetic nephropathy.

Main Methods:

  • Examined TGF-beta system activation in experimental diabetic animal models.
  • Administered neutralizing anti-TGF-beta antibodies to diabetic mice.
  • Assessed renal hypertrophy, mesangial matrix expansion, and renal function.

Main Results:

  • Overexpression of TGF-beta and activation of its signaling pathway (Smad) were observed in diabetic kidneys.
  • Anti-TGF-beta antibody treatment prevented renal hypertrophy and mesangial matrix expansion.
  • Antibody therapy also reversed established diabetic glomerulopathy lesions and preserved renal function.

Conclusions:

  • Kidney TGF-beta system overactivity is a crucial mediator of diabetic renal hypertrophy and matrix expansion.
  • Neutralizing TGF-beta offers a promising therapeutic strategy for diabetic nephropathy.

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.